title: Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.
abstract: OBJECTIVE
  Prostatic inflammation could be a key component in prostate enlargement and benign prostatic hyperplasia (BPH) progression. Our aim was to characterize inflammatory cells infiltrate within BPH tissue and to correlate inflammation and clinical data.
  
  
  METHODS
  Inflammation was profiled on three clinical outcome tissue microarrays (TMAs), including 282 patients treated by surgery for a complicated and/or symptomatic BPH. Inflammation score was defined by combining six cytological parameters and five markers on immunohistochemistry (IHC). Cytological parameters were lymphocytes, macrophages, and polynuclears leukocytes infiltrates, and three glandular aspect modifications: glandular atrophy, glandular destruction, and tissue fibrosis. IHC markers were CD3, CD4, and CD8 decorating T-lymphocytes, CD20 decorating B-lymphocytes, and CD163 decorating macrophages.
  
  
  RESULTS
  The majority of patients had inflammatory cells infiltrating BPH tissues: 81% had T-lymphocytes markers (CD3), 52% had B-lymphocytes markers (CD20), and 82% had macrophages markers (CD163). IPSS score (21 vs. 12; P = 0.02) and prostate volume (77 cm(3) vs. 62 cm(3); P = 0.002) were significantly higher in patients with high-grade prostatic inflammation.
  
  
  CONCLUSIONS
  We characterized inflammatory cells infiltrate in a large cohort of surgically treated BPH specimens. The role of inflammation in BPH development was highlighted by the strong correlation between histological inflammation, IPSS, and prostate volume. Prostate enlargement due to chronic inflammatory process may progressively conduce to BPH progression. Therefore, inflammation is a therapeutic target for BPH.
authors: INSERM U955 Eq07, Créteil, France.
authors: Grégoire
authors: G
authors: Robert
authors: Aurélien
authors: A
authors: Descazeaud
authors: Nathalie
authors: N
authors: Nicolaïew
authors: Stéphane
authors: S
authors: Terry
authors: Nanor
authors: N
authors: Sirab
authors: Francis
authors: F
authors: Vacherot
authors: Pascale
authors: P
authors: Maillé
authors: Yves
authors: Y
authors: Allory
authors: Alexandre
authors: A
authors: de la Taille
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000378:metabolism; D018951:Antigens, CD20 / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D001402:B-Lymphocytes / Q000276:immunology; D015415:Biomarkers / Q000378:metabolism; D017252:CD3 Complex / Q000378:metabolism; D015331:Cohort Studies; D018450:Disease Progression; D006801:Humans; D007150:Immunohistochemistry; D008264:Macrophages / Q000276:immunology; D008297:Male; D046228:Microarray Analysis; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000473:pathology*; D011472:Prostatitis / Q000150:complications* / Q000378:metabolism / Q000473:pathology*; D011956:Receptors, Cell Surface / Q000378:metabolism; D018570:Risk Assessment; D013601:T-Lymphocytes / Q000276:immunology; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D018951:Antigens, CD20; D015214:Antigens, Differentiation, Myelomonocytic; D015415:Biomarkers; D000098902:CD163 Antigen; D017252:CD3 Complex; D011956:Receptors, Cell Surface